- Home
- ANVS vs PSNL Comparison
ANVS vs PSNL Comparison
Compare ANVS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- PSNL
- Stock Information
- Founded
- ANVS 2008
- PSNL 2011
- Country
- ANVS United States
- PSNL United States
- Employees
- ANVS N/A
- PSNL N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- ANVS Health Care
- PSNL Health Care
- Exchange
- ANVS Nasdaq
- PSNL Nasdaq
- Market Cap
- ANVS 44.6M
- PSNL 580.3M
- IPO Year
- ANVS 2020
- PSNL 2019
- Fundamental
- Price
- ANVS $2.67
- PSNL $6.31
- Analyst Decision
- ANVS Strong Buy
- PSNL Strong Buy
- Analyst Count
- ANVS 4
- PSNL 5
- Target Price
- ANVS $18.00
- PSNL $8.00
- AVG Volume (30 Days)
- ANVS 433.2K
- PSNL 1.8M
- Earning Date
- ANVS 08-14-2025
- PSNL 08-06-2025
- Dividend Yield
- ANVS N/A
- PSNL N/A
- EPS Growth
- ANVS N/A
- PSNL N/A
- EPS
- ANVS N/A
- PSNL N/A
- Revenue
- ANVS N/A
- PSNL $85,694,000.00
- Revenue This Year
- ANVS N/A
- PSNL $0.45
- Revenue Next Year
- ANVS N/A
- PSNL $25.75
- P/E Ratio
- ANVS N/A
- PSNL N/A
- Revenue Growth
- ANVS N/A
- PSNL 15.57
- 52 Week Low
- ANVS $1.11
- PSNL $1.61
- 52 Week High
- ANVS $13.91
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- ANVS 57.27
- PSNL 50.64
- Support Level
- ANVS $2.63
- PSNL $6.52
- Resistance Level
- ANVS $2.97
- PSNL $7.32
- Average True Range (ATR)
- ANVS 0.25
- PSNL 0.52
- MACD
- ANVS 0.03
- PSNL -0.11
- Stochastic Oscillator
- ANVS 82.61
- PSNL 22.72
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.